Therapeutic management of patients with COVID-19: a systematic review

  1. M. Tobaiqy
  2. M. Qashqary
  3. S. Al-Dahery
  4. A. Mujallad
  5. A.A. Hershan
  6. M.A. Kamal
  7. N. Helmi

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.infpip.2020.100061
  2. ScreenIT

    SciScore for 10.1101/2020.04.02.20051029: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    The search terms included combinations of: COVID-19, SARS-COV-2, glucocorticoids, chloroquine, convalescent plasma, antiviral, antibacterial, oseltamivir, hydroxychloroquine, chloroquine phosphate, monoclonal antibodies.
    antiviral, antibacterial, oseltamivir, hydroxychloroquine, chloroquine phosphate,
    suggested: None
    Software and Algorithms
    SentencesResources
    Articles for review were selected from electronic databases (Embase, Medline and Google Scholar).
    Embase
    suggested: (EMBASE, RRID:SCR_001650)
    Medline
    suggested: (MEDLINE, RRID:SCR_002185)
    Google Scholar
    suggested: (Google Scholar, RRID:SCR_008878)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Despite these limitations, this is the first systematic review linked the therapeutics used in COVID-19 patients. Furthermore, the review provided up-to-date insight on the current therapeutics’ guidelines for the management of COVID-19 patients, most of reported medicines in this review were already in place in the USA, Saudi Arabia, Europe, and Egypt (Table1). Corticosteroids were the first most commonly mentioned and used medicine in this review; however, it was deemed not recommended in any of the mentioned guidelines. The World Health Organization (WHO) and the United States Centers for Disease Control and Prevention (CDC), in the absence of conclusive scientific evidence, recommended that corticosteroids should not be routinely used in patients with COVID-19 for treatment of viral pneumonia or acute respiratory distress syndrome (ARDS) unless indicated for other conditions, such as asthma or chronic obstructive pulmonary disease (COPD) exacerbation, and septic shock(5,50-51). Careful use of corticosteroids with low-to-moderate doses and short courses of treatment is advised. Hyperglycemia, hypernatremia, and hypokalemia are the most common adverse effects associated with corticosteroids’ use and should be routinely monitored (5,51). Lopinavir/ritonavir is available as the brand name (Kaletra) and was the second most reported medicine in this review. Cao B and colleagues showed in their RCT negative outcomes of this HIV treatment for COVID-19 patients (Table 2) (30,52-54...

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    NCT04252885CompletedThe Efficacy of Lopinavir Plus Ritonavir and Arbidol Against…

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.04.02.20051029v1 on medRxiv